Global Animal Genetics Market Size, Share & Forecast, By Product Type, Species & Technology, 2026-2031

The Global Animal Genetics Market was valued at USD 7.8 billion in 2025. The estimate includes commercial breeding animals, semen, embryos, genomic testing, genetic services and breeding-data platforms, while excluding veterinary pharmaceuticals, feed products and unrelated animal biotechnology. Genetic material remained the largest revenue pool because it provides recurring access to elite bovine, porcine, poultry and aquaculture traits. Testing and data services increased their economic importance as producers sought higher selection accuracy, traceability and health-risk management. North America remained the largest regional market because of its integrated production systems and advanced genomic infrastructure.

The market is projected to reach USD 11.8 billion by 2031, representing a 7.09% CAGR from the 2025 base. Approximately five percentage points of annual expansion are expected from higher transaction volumes, including semen doses, embryos, breeding-stock equivalents and genomic tests. The balance should come from price and mix improvements driven by sexed semen, genetic testing, software subscriptions, advanced reproductive services and performance-linked royalties. Asia-Pacific and the Middle East and Africa are expected to grow faster than mature regions because commercial genomic penetration remains comparatively low.

Profit pools are shifting from one-time sales of breeding animals toward recurring genetic-material, testing, analytics and royalty revenues. Semen and embryos remain commercially important, but genomic data strengthens customer retention by linking each breeding decision to predicted performance and future herd outcomes. Disease-resistance traits can support outcome-based pricing because their value is measurable against avoided mortality, treatment and production losses. Software and testing also require less biological inventory than live-animal businesses, supporting more scalable economics once laboratories, databases and customer workflows are established.

Regulatory fragmentation is the most important constraint for advanced genetic technologies. A trait approved for food production in one country may remain commercially unusable in export markets that apply different biotechnology, animal-breeding or traceability requirements. This can delay global dissemination and reduce the return on long research programs. Conventional genomic selection faces fewer consumer concerns but still depends on data quality, recognized breed registries and cross-border germplasm certification. Companies must therefore design regulatory strategies alongside trait development rather than treating approval as a final commercialization step.

Asia-Pacific offers the strongest large-scale growth opportunity, with a modeled CAGR of 9.10% through 2031. The region combines rising meat, dairy, egg and aquaculture demand with lower genomic penetration than North America or Europe. China, India and Southeast Asia require higher animal productivity while managing land, feed, water and biosecurity constraints. Commercial opportunities include locally adapted semen, poultry parent stock, aquaculture broodstock, genomic testing and public-private herd-improvement programs. Market access depends on local multiplication partners, artificial-insemination coverage and credible performance data under regional production conditions.

The central demand factor is the widening gap between animal-source food output and herd expansion. Global meat, dairy and egg production is projected to rise by 17% through 2034, while inventories of cattle, sheep, pigs and poultry increase by only 7%. Producers must therefore generate more output per animal through improved feed efficiency, fertility, survival, health and product quality. Genetics captures value because improvements accumulate across generations and can reduce operating costs throughout the production cycle rather than delivering only a temporary input benefit.

Gene editing will increase competitive differentiation but is unlikely to replace conventional selection or genomic breeding. Edited disease-resistance and welfare traits can create defensible intellectual property and support premium royalties when they solve high-cost production problems. However, approval requirements, consumer acceptance and international trade recognition will limit early deployment to selected species and jurisdictions. Incumbents with large nucleus populations, biosecure multiplication systems and established producer relationships have an advantage because they can integrate edited traits into proven commercial lines and distribute them rapidly after approval.